Quarterly Financial Results for Period Ending June 30, 2026 - Contains consolidated financial statements including balance sheet as of June 30, 2026 and December 31, 2025, income statements for Q2 2026 and six-month period ended June 30, 2026, and comparative periods from 2025 Business Segment Performance - Reports financial results segmented by Products and Services divisions for the three-month…

Our analysis rates this filing CAUTIOUS. Northrop Grumman's Q2 2026 filing reveals elevated but not critical concerns. The identification of three new risks concentrated in a single quarter, particularly the severity-7 issue on the B-21 program (the company's largest defense contract), warrants…

Concern level: HIGH (6.2/10). Key factors: One high-severity risk identified (B-21 Program accounting estimate changes, severity 7/10) on company's largest defense program with repeated adjustments across multiple LRIP option phases; Two moderate-to-high severity risks (GEM 63XL and SIAW programs, severity 6/10 each) showing accounting estimate adjustments indicating cost overruns or schedule…

Notable risk changes: Multiple accounting estimate adjustments on percentage-of-completion contracts indicate cost growth or schedule delays on B-21, GEM 63XL, and SIAW programs - suggests execution challenges on critical defense/space contracts; Pattern of estimate revisions across Defense Systems and Space Systems segments in Q2 2026 raises questions about program management and cost control effectiveness; B-21…

The model predicts NOC will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.